The addition of 2.4% hydrogen to hypoxia patients’ traditional ventilation gases improved neurologic outcomes and reduced tissue injury in a recent study of piglets, suggesting hydrogen might be a beneficial addition to therapy for babies undergoing surgery for congenital heart disease (CHD).

Boston Scientific’s LOTUS Edge Aortic Valve System was cleared by the FDA April 23 for use in high-risk surgical candidates with severe aortic stenosis.

Transsubclavian or transaxillary (TAx) access has become the preferred route for balloon-expandable TAVR when femoral access isn’t feasible, a new analysis found. Outcomes were generally favorable with TAx TAVR compared to other alternative access techniques, with the exception of higher stroke rates, researchers reported in JACC: Cardiovascular Interventions.

With CMS just months away from an updated national coverage determination for transcatheter aortic valve replacement (TAVR), a new analysis in the New England Journal of Medicine suggests the relationship between procedural volume and TAVR outcomes remains important in the United States.

When pregnant women inhale secondhand smoke—including from prospective fathers—it may be even more dangerous to their offspring than if the women smoke themselves, according to a meta-analysis published in the European Journal of Preventive Cardiology.

An expert consensus statement published by the Society for Cardiovascular Angiography and Interventions (SCAI) offers guidance for the safe and effective use of patent foramen ovale (PFO) closure devices to prevent recurrent stroke.

Patients with severe but asymptomatic aortic stenosis have better survival two and three years later if an aortic valve replacement (AVR) is initially recommended instead of a “watchful waiting” approach, according to a single-center study published in The Annals of Thoracic Surgery.

NEW ORLEANS — Patients who received the MitraClip device to treat heart failure with secondary mitral regurgitation showed significant and lasting improvements on a quality-of-life assessment compared to people treated with optimal medical therapy alone, according to a substudy of the COAPT trial presented at the American College of Cardiology’s scientific sessions.